Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: peptide therapeutics - Zealand Pharma

Drug Profile

Research programme: peptide therapeutics - Zealand Pharma

Alternative Names: ZP 7570; ZP-1-98; ZP-3022; ZP-DI-70; ZP2435

Latest Information Update: 23 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zealand Pharma
  • Class Antihyperglycaemics; Obesity therapies; Peptides
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Gastrin modulators; Glucagon receptor agonists; Glucagon-like peptide 1 stimulants; Glucagon-like peptide 2 stimulants; Glucagon-like peptide-1 receptor antagonists; Neuropeptide Y inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gastrointestinal disorders; Short bowel syndrome
  • No development reported Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 15 Nov 2018 Preclinical trials in Gastrointestinal disorders in Denmark (unspecified route)
  • 15 Nov 2018 Preclinical trials in Short bowel syndrome in Denmark (unspecified route)
  • 15 Nov 2018 Zealand Pharma plans a phase I trial for Short bowel syndrome in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top